Illumina, Inc. (ILMN) Rating Reiterated by Piper Jaffray Companies

Illumina, Inc. (NASDAQ:ILMN)‘s stock had its “overweight” rating restated by equities research analysts at Piper Jaffray Companies in a report released on Monday. They currently have a $226.00 price objective on the life sciences company’s stock, up from their prior price objective of $202.00. Piper Jaffray Companies’ price objective points to a potential upside of 10.70% from the stock’s current price.

A number of other brokerages have also commented on ILMN. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $200.00 target price on shares of Illumina in a research report on Tuesday, September 26th. Vetr raised shares of Illumina from a “hold” rating to a “buy” rating and set a $217.50 target price on the stock in a research report on Tuesday, September 19th. Argus raised their target price on shares of Illumina from $205.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, September 13th. Leerink Swann reaffirmed an “outperform” rating and set a $225.00 target price (up from $207.00) on shares of Illumina in a research report on Tuesday, September 12th. Finally, BidaskClub lowered shares of Illumina from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company. Illumina currently has a consensus rating of “Hold” and an average price target of $184.86.

Illumina (NASDAQ ILMN) opened at 204.15 on Monday. Illumina has a 12-month low of $119.37 and a 12-month high of $214.34. The stock has a 50 day moving average price of $203.36 and a 200 day moving average price of $185.15. The stock has a market cap of $29.81 billion, a P/E ratio of 40.96 and a beta of 0.76.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company had revenue of $662.00 million for the quarter, compared to analyst estimates of $642.38 million. During the same period in the prior year, the company posted $0.86 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, analysts forecast that Illumina will post $3.65 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.themarketsdaily.com/2017/10/11/illumina-inc-ilmn-rating-reiterated-by-piper-jaffray-companies.html.

In other news, SVP Oene Mark Van sold 9,729 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $211.33, for a total value of $2,056,029.57. Following the completion of the transaction, the senior vice president now owns 24,908 shares in the company, valued at approximately $5,263,807.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michel Bouchard sold 616 shares of the stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,200.00. Following the completion of the transaction, the chief accounting officer now owns 15,161 shares of the company’s stock, valued at approximately $3,032,200. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 178,516 shares of company stock valued at $34,995,591. 1.60% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the business. Advisory Services Network LLC boosted its stake in shares of Illumina by 13.0% during the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after purchasing an additional 89 shares during the last quarter. Penserra Capital Management LLC boosted its stake in shares of Illumina by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after purchasing an additional 102 shares during the last quarter. Paradigm Asset Management Co. LLC boosted its stake in shares of Illumina by 5.6% during the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after purchasing an additional 50 shares during the last quarter. Patten Group Inc. boosted its stake in shares of Illumina by 2.7% during the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after purchasing an additional 25 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. boosted its stake in shares of Illumina by 11.3% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 93.32% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply